FOLLOWUS
Identification of human serum protein targets of Qianggu Decoction (强骨饮) in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology
- Chinese Journal of Integrative Medicine Vol. 23, Issue 10, Pages: 747-754(2017)
- Affiliations：
1. The Second Clinical Medical College, Zhejiang Chinese Medical University,Hangzhou,China
2. Department of Ortopaedics and Traumatology, the Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China
3. Department of Diagnostics of Traditional Chinese Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University,Hangzhou,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 81373878) and Natural Science Foundation of Zhejiang Province, China (No. LY13H290009 and No. LY12H29007)
DOI：10.1007/s11655-016-2600-4
CLC：Published：2017，
Published Online：7 July 2016，
Scan for full text
Liang, Bc., Shi, Xl., Li, Cw. et al. Identification of human serum protein targets of Qianggu Decoction (强骨饮) in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology., Chin. J. Integr. Med. 23, 747–754 (2017). https://doi.org/10.1007/s11655-016-2600-4
Bo-cheng Liang, Xiao-lin Shi, Chun-wen Li, et al. Identification of human serum protein targets of Qianggu Decoction (强骨饮) in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology. [J]. Chinese Journal of Integrative Medicine 23(10):747-754(2017)
Liang, Bc., Shi, Xl., Li, Cw. et al. Identification of human serum protein targets of Qianggu Decoction (强骨饮) in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology., Chin. J. Integr. Med. 23, 747–754 (2017). https://doi.org/10.1007/s11655-016-2600-4 DOI：
Bo-cheng Liang, Xiao-lin Shi, Chun-wen Li, et al. Identification of human serum protein targets of Qianggu Decoction (强骨饮) in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology. [J]. Chinese Journal of Integrative Medicine 23(10):747-754(2017) DOI： 10.1007/s11655-016-2600-4.
摘要
To investigate the serum protein targets of Qianggu Decoction (强骨饮
QGD) on treating osteoporosis by the proteomics analysis using tandem mass tag (TMT) and liquid chromatographytandem mass spectrometry (LC-MS/MS). Twenty serum protein samples were recruited (10 patients with primary type I osteoporosis before and after QGD treatment) and the high abundance ratios protein was removed
two serum samples were extracted and labeled with TMT reagent. Then
mass spectrometric detection
identification of differentially expressed proteins and bioinformatics analysis of differentially expressed proteins were carried out. A total of 60 proteins were identified
within a 99% confidence interval
to be differentially regulated of which
34 proteins were up-regulated and 26 proteins were down-regulated. Differentially expressed proteins analyzed by Gene Ontology (GO) annotation mainly get involved in 12 different biological processes
7 types of cellular components
and 6 kinds of molecular functions. Angiotensinogen (AGT)
stromelysin-1 (MMP3)
heparanase (HPSE) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were screened as candidate protein targets of QGD treatment
which were related to metabolic mechanism of bone remodeling and/or bone collagen of osteoporosis. By the utilization of the protein-protein interaction network analysis tool named STRING10.0
it showed that AGT
MMP3
HPSE and GAPDH were located in the key node of the protein-protein interactions network. Furthermore
AGT
MMP3
HPSE and GAPDH were found to be directly related to BMP
MAPK
Wnt
SMAD and tumor necrosis factor ligand superfamily member 11 (TNFSF11) families. The proteomics analysis by using TMT combined with LC-MS/MS was a feasible method for screening the potential therapeutic targets associated with QGD treatment. It suggests that AGT
MMP3
HPSE and GAPDH may be candidate protein targets of QGD treatment which can be used as therapeutic effect monitor and early diagnosis of primary type I osteoporosis.
Abstract
To investigate the serum protein targets of Qianggu Decoction (强骨饮
QGD) on treating osteoporosis by the proteomics analysis using tandem mass tag (TMT) and liquid chromatographytandem mass spectrometry (LC-MS/MS). Twenty serum protein samples were recruited (10 patients with primary type I osteoporosis before and after QGD treatment) and the high abundance ratios protein was removed
two serum samples were extracted and labeled with TMT reagent. Then
mass spectrometric detection
identification of differentially expressed proteins and bioinformatics analysis of differentially expressed proteins were carried out. A total of 60 proteins were identified
within a 99% confidence interval
to be differentially regulated of which
34 proteins were up-regulated and 26 proteins were down-regulated. Differentially expressed proteins analyzed by Gene Ontology (GO) annotation mainly get involved in 12 different biological processes
7 types of cellular components
and 6 kinds of molecular functions. Angiotensinogen (AGT)
stromelysin-1 (MMP3)
heparanase (HPSE) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were screened as candidate protein targets of QGD treatment
which were related to metabolic mechanism of bone remodeling and/or bone collagen of osteoporosis. By the utilization of the protein-protein interaction network analysis tool named STRING10.0
it showed that AGT
MMP3
HPSE and GAPDH were located in the key node of the protein-protein interactions network. Furthermore
AGT
MMP3
HPSE and GAPDH were found to be directly related to BMP
MAPK
Wnt
SMAD and tumor necrosis factor ligand superfamily member 11 (TNFSF11) families. The proteomics analysis by using TMT combined with LC-MS/MS was a feasible method for screening the potential therapeutic targets associated with QGD treatment. It suggests that AGT
MMP3
HPSE and GAPDH may be candidate protein targets of QGD treatment which can be used as therapeutic effect monitor and early diagnosis of primary type I osteoporosis.
关键词
primary type I osteoporosistonifying qi and warming meridiansChinese Medicineproteomics
Keywords
primary type I osteoporosistonifying qi and warming meridiansChinese Medicineproteomics
references
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23–57.
Zhang ZH, Liu ZH, Shi SH, LI YN. A retrospective literature study of osteoporosis incidence based on-2.5 SD criteria in mainland China. Chin J Osteoporos (Chin) 2015;21:1–24.
Ganda K, Puech M, Chen J, Speerin R, Bleasel J, Center J, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and metaanalysis. Osteoporos Int 2013;24:393–406.
Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 2011;26:553–560.
Xu DP, Wu HL, Lan TH, Wang X, Sheng XG, Lin Y, et al. Effect of Shenzhu Guanxin Recipe on patients with angina pectoris after percutaneous coronary intervention: a prospective, randomized controlled trial. Chin J Integr Med 2015;21:408–416.
Li XY, Sun F, Li JW, Pan DQ, Shi XL,Kan LJ. Research progress of nourishing qi and warm meridian prescription and strong bone drink in the treatment of primary osteoporosis. Chin J Osteoporos (Chin) 2014;20:1003–1006.
Schirle M, Bantscheff M,Kuster B. Mass spectrometrybased proteomics in preclinical drug discovery. Chem Biol 2012;19:72–84.
Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 1999;10:259–264.
Shi XL, Li CW, Liang BC, He KH and Li XY. Weak cation magnetic separation technology and MALDI-TOF-MS in screening serum protein markers in primary type I osteoporosis. Genet Mol Res 2015;14:15285–15294.
Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publiclyavailable database. Proteomics 2005;5:3226–3245.
Millioni R, Tolin S, Puricelli L, Sbrignadello S, Fadini GP, Tessari P, et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011;6:e19603.
Sinclair J, Timms JF. Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods 2011;54:361–369.
Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, and Rochat B. Comparison between a high-resolution single-stage orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun Mass Sp 2012;26:499–509.
Stypka L, Kozielski M, eds. Methods of gene ontology term similarity analysis in graph database environment, in beyond databases, architectures, and structures. Ustron: Springer; 2014:345–354.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-D452.
Demchak B, Hull T, Reich M, Liefeld T, Smoot M, Ideker T, et al. Cytoscape: the network visualization tool for GenomeSpace workflows [version 2]. F1000Research 2014;3:151.
Xie YM, Yuwen Y, Dong FH, Sun SC, Wang HM, Liu QS, et al. Clinical practice guideline of traditional medicine for primary osteoporosis. Chin J Integr Med 2011;17:52–63.
Shu B, Shi Q, Wang Y. Shen (Kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome. Chin J Integr Med 2015;21:656–661.
Li Y, Xue L, Zhao F. Distribution of Chinese syndrome types in patients with primary osteoporosis and its relationship with bone fracture. Chin J Integr Tradit West Med (Chin) 2010;30:493–495.
Wang X, Zhang A, Wang P, Sun H, Wu G, Sun W, et al. Metabolomics coupled with proteomics advancing drug discovery toward more agile development of targeted combination therapies. Mol Cell Proteomics 2013;12:1226–1238.
Nanjappa V, Thomas JK, Marimuthu A, Muthusamy B, Radhakrishnan A, Sharma R, et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res 2014;42:D959-D965.
Wang Y, Chuo WJ, Li C, Guo SZ, Chen JX, Yu JD, et al. Energy metabolism disorder and myocardial injury in chronic myocardial ischemia with qi deficiency and blood stasis syndrome based on 2-DE proteomics. Chin J Integr Med 2013;19:616–620.
Al-Daghri NM, Al-Attas OS, Johnston HE, Singhania A, Alokail MS, Alkharfy KM, et al. Whole serum 3D LC-nESIFTMS quantitative proteomics reveals sexual dimorphism in the Milieu Intérieur of overweight and obese adults. J Proteome Res 2014;13:5094–5105.
Hughes AT, Milan AM, Davison AS, Christensen P, Ross G, Gallagher JA, et al. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem 2015;52:597–605.
Sinclair J, Timms JF. Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods 2011;54:361–369.
Jones KA, Kim PD, Patel BB, Kelsen SG, Braverman A, Swinton DJ, et al. Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers. J Proteome Res 2013;12:4351–4365.
Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007;115:725–732.
Kwok T, Leung J, Zhang Y, Bauer D, Ensrud K, Barrett- Connor E, et al. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporosis Int 2012;23:2159–2167.
Gu SS, Zhang Y, Li XL, Wu SY, Diao TY, Hai R, et al. Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice. Biosci Biotech Bioch 2012;76:1367–1371.
Itakura M, Nakajima H, Semi Y, Higashida S, Azuma Y-T, Takeuchi T. Glyceraldehyde-3-phosphate dehydrogenase aggregation inhibitor peptide: a potential therapeutic strategy against oxidative stress-induced cell death. Biochem Biophys Res Commun 2015;467:373–376.
Benavides GA, Liang Q, Dodson M, Darley-Usmar V, Zhang J. Inhibition of autophagy and glycolysis by nitric oxide during hypoxia-reoxygenation impairs cellular bioenergetics and promotes cell death in primary neurons. Free Radical Bio Med 2013;65:1215–1228.
Li G, Pan Y, Sirois P, Li K, Xu Y. Iron homeostasis in osteoporosis and its clinical implications. Osteoporosis Int 2012;23:2403–2408.
Weinberg E. Role of iron in osteoporosis. Pediatr Endocr Rev 2008;6:81–85.
Hoshi K, Nomura K, Sano Y, Koshihara Y. Nuclear vitamin K 2 binding protein in human osteoblasts: homologue to glyceraldehyde-3-phosphate dehydrogenase. Biochem Pharmacol 1999;58:1631–1638.
Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res 2014;20:3071–3077.
Yi D. Correlation of circulating matrix metalloproteinase-3 and osteopontin levels with postmenopausal osteoporosis. J Trauma Treat 2013;2:2167–1222.
Garcia AJ, Tom C, Guemes M, Polanco G, Mayorga ME, Wend K, et al. ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res 2013;28:283–290.
0
Views
0
Downloads
2
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
